Why does testing matter without symptoms?
Hepatitis B and hepatitis C are different infections that affect the liver, and either may be present for some time without clear symptoms. Fatigue, nausea or jaundice can occur, but their absence does not make testing unnecessary. Diagnosis therefore cannot rest on how someone feels or looks. Blood tests identify markers of current or previous infection, and a clinician then interprets them with the medical history and the rest of the assessment [4, 8, 9, 11].
Viral testing is also not the same as a liver-function panel. ALT, AST and the other liver measurements may help assess irritation or damage, but they neither prove hepatitis B or C nor exclude infection when normal. A virus-specific test answers a different question, and a positive result may then lead to a separate assessment of liver health. If your main question concerns high or normal liver-panel values, the linked guide covers that topic without repeating it here [1, 6, 9].
The aim is not to order the largest possible panel. It is to define the question: Is this first-time screening without symptoms, testing after a recent exposure, follow-up of an older positive result, or follow-up after treatment? Each situation has a different test sequence and timing. A clear plan prevents an HCV antibody or an isolated HBsAg result from being treated as if it were the complete answer [1, 6, 12].
Who should be tested for hepatitis C or B?
CDC guidance recommends hepatitis C screening at least once for all adults and during every pregnancy, with repeat testing when exposure or ongoing risk is present. Important reasons for assessment include sharing injection equipment, maintenance dialysis, occupational blood exposure, HIV, birth to a mother with HCV, or persistently abnormal ALT without an explanation. These are public-health recommendations; a clinician can adapt them to the country, your history and the type of exposure [1, 4].
For hepatitis B, current CDC guidance recommends that every adult be screened at least once with the triple panel, that pregnant patients be screened during every pregnancy, and that people with ongoing exposure or higher likelihood of infection receive appropriate testing or follow-up. Examples include household or sexual contact with an infected person, shared blood-contaminated equipment, dialysis, occupational exposure, or birth in a region where HBV is common. WHO also recommends access to HBsAg testing for adults in intermediate- or high-prevalence settings and targeted testing for pregnant people and higher-risk groups [6, 7, 8].
After a recent blood or needlestick exposure, do not wait for symptoms or choose the testing date yourself. Contact a medical service promptly because the virus involved, timing, hepatitis B vaccination status and the source person’s result, when known, can all change the plan. You do not have to disclose a stigmatised risk before being allowed to test: CDC says that a person’s request is enough reason to offer hepatitis B or C testing because some people may be reluctant to describe a particular risk [1, 6].
Hepatitis C testing: antibody is not PCR
The usual first step is an HCV antibody test, often written as HCV antibody or anti-HCV. A nonreactive result means that antibodies were not detected and excludes infection in most situations involving an older exposure. After a recent exposure, however, antibodies may not yet be detectable. CDC explains that antibody development can be delayed, so a clinician may request HCV RNA rather than rely on the antibody result alone [1].
A reactive or positive antibody test means that the body encountered HCV at some point; it does not necessarily mean that the virus is present now. It can represent current infection, a past infection that has resolved, or occasionally biologic false positivity. Current infection is identified with a nucleic-acid test for HCV RNA, commonly called PCR. Ideally, the laboratory performs RNA testing automatically on the same sample after a reactive antibody result so the confirmation step is not lost [1, 12].
Detected HCV RNA establishes current infection and should lead to care and treatment assessment. If antibody is positive but RNA is not detected, there is no current infection in most cases; the body may have cleared the infection or treatment may have succeeded. A clinician may repeat or expand testing after a recent exposure, concern about the specimen, or an immune condition that changes interpretation. Do not use the antibody level as a substitute for viral load, and do not treat the word “positive” as a complete diagnosis without the RNA line [1, 4].
Hepatitis B testing: HBsAg and the triple panel
For hepatitis B, HBsAg is the hepatitis B surface antigen. Its presence generally indicates current infection, either acute or chronic, but it does not explain the phase or immune status on its own. First-time adult screening therefore uses a triple panel: HBsAg, antibody to surface antigen (anti-HBs), and total antibody to core antigen (total anti-HBc). Reading the three together can distinguish current infection, resolved past infection, vaccine-associated immunity and susceptibility [6, 7].
Anti-HBs alone with negative total anti-HBc, in the setting of a documented completed vaccine series, fits immunity from vaccination. Total anti-HBc indicates past or current exposure to the virus; vaccination alone does not produce core antibody. Positive HBsAg with positive total anti-HBc requires linkage to hepatitis B care, while IgM anti-HBc helps when acute infection is suspected. An isolated positive total anti-HBc has several possible explanations, so it cannot be reduced to one sentence without review [6, 7].
After HBV infection is identified, a clinician may request HBV DNA to measure the amount of virus and arrange blood tests and assessment of liver health. Persistence of HBsAg over time contributes to distinguishing acute from chronic infection; one report should not be used to decide the type without context. A fully negative triple panel may indicate susceptibility when there is no documented completed vaccination, allowing the clinician to discuss vaccination according to guidance and the person’s health situation [6, 7, 9].
Can hepatitis C be cured, and is hepatitis B the same?
Yes. Hepatitis C can be treated with direct-acting antivirals (DAAs), and CDC and WHO report cure in more than 95% of cases, usually with a short course of oral treatment. That population figure is not an individual promise. Regimen and duration depend on assessment, prior treatment, liver status, accompanying conditions and medicine interactions. Do not start, stop or switch treatment yourself, and give the clinician a complete list of medicines and supplements [2, 3, 4].
“Cured” is not established merely by finishing the tablets or seeing better liver enzymes. CDC defines sustained virologic response by undetectable HCV RNA 12 weeks after treatment ends, indicating virologic cure. Antibody can remain positive after cure, so testing for possible reinfection in a previously treated person relies on HCV RNA rather than repeating antibody alone. Cure also does not create immunity against a new infection after another exposure [2, 4, 11].
Hepatitis B is different. Antiviral treatment can suppress the virus, slow progression of cirrhosis and reduce complications, but current treatment is not described as curative in the same way as hepatitis C therapy. Not everyone with chronic HBV needs medication immediately; the decision depends on HBV DNA, liver tests, fibrosis and other factors. Anyone who starts treatment should not stop it independently. Regular follow-up remains central whether medication begins or the clinician is monitoring the condition [8, 9, 10].
Follow-up after the result and Egypt’s context
In 2023, WHO announced that Egypt was the first country to reach gold-tier status on the path to hepatitis C elimination under WHO criteria. WHO reported that the “100 Million Healthy Lives” campaign tested more than 60 million people and treated more than 4 million. This is an important achievement, but it does not mean an old result replaces assessment after a new exposure or that everyone knows their current status from memory of the campaign. The written result, test type and date are what should be reviewed [5].
After detectable HCV RNA, evaluation includes liver status, possible coinfections and medicines before treatment is selected. After cure, follow-up depends on the liver damage present before treatment and whether exposure continues; a person with advanced fibrosis may still need liver follow-up after the virus is cleared. After a positive HBV result, monitoring may include HBV DNA, liver blood tests, fibrosis assessment or imaging according to the situation. Ultrasound has a defined role, but it cannot diagnose the infection in place of a blood test [2, 4, 9, 10].
If a report also mentions fatty liver, that is a parallel issue rather than an automatic explanation of the viral result. More than one factor may need attention, and the clinician can order the priorities without confusing viral infection with liver fat. The linked pages explain what ultrasound can show and how possible fatty liver is assessed, while this page remains focused on hepatitis B and C testing [4, 9].
When is urgent care needed, and how do you prepare?
Seek urgent assessment for new and obvious yellowing of the eyes or skin, persistent vomiting with inability to drink, unusual drowsiness or confusion, bleeding, rapidly increasing abdominal swelling, or marked deterioration in general condition. These features do not identify the virus by themselves, but they can accompany an acute illness or liver problem that should not wait for a routine appointment. After a recent needlestick or blood exposure, contact a medical service promptly even if you feel well [4, 8, 9].
For a routine appointment, bring the complete report rather than a cropped image. Record the name and date of every test: HCV antibody, HCV RNA or PCR, HBsAg, anti-HBs, total anti-HBc, and any HBV DNA. Also bring older liver tests, a list of medicines and supplements, your hepatitis B vaccination record, and details of any previous hepatitis C treatment. State when a possible exposure occurred without blaming yourself or anyone else; accurate medical information helps select the right test and timing [1, 6, 9].
Do not share razors, toothbrushes or equipment that may carry blood, and do not donate blood when you have current infection or a result is still unresolved. Hepatitis C does not spread through hugging, shared food or coughing, and hepatitis B does not spread through handshakes or sharing meals; ordinary daily contact is not a reason for isolation. If you need the result explained and a next-step plan, you can book with the medical team at La Rose in Maadi or Fifth Settlement, New Cairo. If an urgent feature is present, use urgent care instead of waiting for a booking [4, 8, 11]. For non-urgent concerns, you can book a consultation with the medical team.
